What Did the Confirmatory Phase 3 MDMA-Assisted Therapy Trial Add?
The first Phase 3 trial of MDMA-assisted therapy for severe post-traumatic stress disorder reported a favorable difference over therapy with placebo. A second confirmatory trial, MAPP2, asked whether that result would replicate in a more diverse group that included both moderate and severe PTSD.
This article focuses on what the second trial added. For context, see the earlier discussion of the first Phase 3 trial and its limitations.
How was MAPP2 designed?
The multisite study randomized 104 adults: 53 to MDMA-assisted therapy and 51 to placebo with the same manualized therapy. Participants completed preparation sessions, three eight-hour experimental sessions approximately one month apart, and integration sessions. The MDMA group received split doses totaling 120 mg during the first session and up to 180 mg during later sessions.
Independent blinded assessors measured PTSD severity with the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) and functional impairment with the Sheehan Disability Scale. The primary comparison was change from baseline through approximately 18 weeks.
What did the trial report?
The least-squares mean CAPS-5 reduction was 23.7 points in the MDMA-assisted therapy group and 14.8 points in the placebo-plus-therapy group. The between-group effect size was reported as Cohen’s d = 0.7. Functional impairment also improved more in the MDMA group: a 3.3-point reduction versus 2.1 points on the Sheehan scale.
Among 52 MDMA-group participants assessed at study end, 45 met the trial’s definition of clinically meaningful response and 37 no longer met PTSD diagnostic criteria. Those are within-group outcome classifications; the randomized between-group contrast remains the more important evidence for efficacy.
What was new about the participant population?
About 27% of participants had moderate PTSD and 73% had severe PTSD. Approximately half of the sample identified as ethnically or racially diverse, including 26.9% who identified as Hispanic or Latino and 33.7% who identified as other than White. The trial also included people with depression, dissociative features, varied trauma histories, and some alcohol or cannabis risk.
That broader representation improves relevance compared with a narrowly homogeneous trial. It does not make the study representative of every patient with PTSD.
What safety findings were reported?
Every MDMA-group participant and 96.1% of placebo-group participants reported at least one treatment-emergent adverse event. Five MDMA participants and two placebo participants had a severe event, but the paper reported no serious treatment-emergent adverse events and no deaths. Common events more frequent with MDMA included muscle tightness, nausea, decreased appetite, sweating, feeling hot, jaw clenching, restlessness, and transient cardiovascular changes.
Participants with current serious suicide risk, important cardiovascular disease, certain personality disorders, and many substance-use disorders were excluded. Safety conclusions therefore apply to a screened and closely monitored clinical-trial population, not unsupervised MDMA use.
What did the second trial not resolve?
Functional blinding remains difficult when a drug has recognizable psychoactive effects. The investigators used independent assessors and a blinding survey, but expectancy could not be eliminated. Dropout also differed: 1.9% in the MDMA group and 15.7% in the placebo group. The trial followed the acute treatment course and assessed the primary endpoint only about two months after the final session, leaving durability and longer-term misuse risk for further study.
The study did not directly compare MDMA-assisted therapy with SSRIs, prolonged exposure, cognitive processing therapy, or other established treatments. Larger effect sizes across separate studies cannot establish superiority without a head-to-head trial.
MAPS funded and organized the study through its public-benefit corporation, oversaw data collection and interpretation, and funded medical writing support. Multiple authors reported MAPS-related roles or payments. Disclosure does not invalidate the trial, but independent replication and data access remain important.
Bottom line
MAPP2 replicated favorable symptom and functional outcomes in a more ethnoracially diverse population with moderate-to-severe PTSD. It strengthened the evidence that the observed benefit was not confined to the first Phase 3 sample. It did not resolve expectancy, long-term effectiveness, broad clinical eligibility, comparative effectiveness, or sponsor-independence questions.
This article is educational and is not medical advice. MDMA-assisted treatment should not be equated with unsupervised MDMA use.
Scientific source
Mitchell J.M. et al. “MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial.” Nature Medicine (2023). DOI: 10.1038/s41591-023-02565-4. PubMed PMID 37709999.
